Prosecution Insights
Last updated: May 04, 2026
Application No. 17/791,182

SENSOR FOR DETECTING A TARGET ANALYTE IN A LIQUID MEDIUM WITH AN OPTICAL RESONATOR COUPLED TO A MECHANICAL RESONATOR

Final Rejection §112
Filed
Jul 06, 2022
Priority
Jan 08, 2020 — FR FR2000129 +1 more
Examiner
GROSS, CHRISTOPHER M
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITE PARIS CITE
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
412 granted / 653 resolved
+3.1% vs TC avg
Strong +41% interview lift
Without
With
+41.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
36 currently pending
Career history
689
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
31.8%
-8.2% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 653 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Responsive to communications entered 2/19/2026 Claims cancelled 1-18 Claims pending 19-38 Claims currently under consideration 19-38 Priority This application has a filing date of 07/06/2022 and is a 371 of PCT/FR2021/050022 filed 01/08/2021. Acknowledgment is made of applicant's claim for foreign priority based on an application filed in France on 01/08/2020. Receipt is acknowledged of certified copies of document no. 2000129 required by 37 CFR 1.55. Withdrawn Objection(s) and/or Rejection(s) All rejections from the previous action have been overcome by Applicant’s amendments. New Claim Rejection(s) – 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 19-38 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection concerns new matter. Sole independent amended claim 19 adds the limitation of a ‘metallic adhesion layer’ to the penultimate line, whereas the current remarks urge support therefor may be found at paragraphs 67-75 of the present published application. In reviewing such passages, however the examiner finds no description whatsoever of a metallic adhesion layer, consequently the disclosure as originally filed provided no implicit or explicit support for such addition, nor do the remarks accompanying the current amendment point to where the new material is disclosed in the current application’s priority documents. Applicants are reminded that it is their burden to show where the specification supports any amendments to the disclosure. See MPEP 714.02, paragraph 5, last sentence and also MPEP 2163.06 I. MPEP 2163.06 notes “If new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981).” MPEP 2163.02 teaches that “Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application. MPEP 2163.06 further notes “When an amendment is filed in reply to an objection or rejection based on 35 U.S.C. 112, first paragraph, a study of the entire application is often necessary to determine whether or not “new matter” is involved. Applicant should therefore specifically point out the support for any amendments made to the disclosure. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER M GROSS whose telephone number is (571)272-4446. The examiner can normally be reached M-F 10-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached on (571)272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTOPHER M GROSS/ Primary Examiner, Art Unit 1684
Read full office action

Prosecution Timeline

Jul 06, 2022
Application Filed
Sep 19, 2025
Non-Final Rejection — §112
Feb 19, 2026
Response Filed
Apr 04, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12613250
BIOMARKER PANEL FOR SEPSIS ENCEPHALOPATHY
4y 5m to grant Granted Apr 28, 2026
Patent 12612621
METHODS OF SELECTING BINDING REAGENTS
2y 3m to grant Granted Apr 28, 2026
Patent 12577555
SCREENING METHOD FOR TELOMERASE REVERSE TRANSCRIPTASE (TERT) PHOSPHORYLATION INHIBITORS
5y 9m to grant Granted Mar 17, 2026
Patent 12558350
COMPOSITIONS AND METHODS FOR TREATMENT
3y 7m to grant Granted Feb 24, 2026
Patent 12553892
ASSAYS FOR ANTIMICROBIAL ACTIVITY AND APPLICATIONS THEREOF
4y 3m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+41.0%)
4y 2m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 653 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month